X hits on this document

Powerpoint document

Considerations for Exposure to Diazinon and Chlorpyrifos - page 46 / 49





46 / 49

References from our laboratory

Mueller, R. F., Hornung, S., Furlong, C. E., Anderson, J., Giblett, E. R. and Motulsky, A. G.  1983.  Plasma paraoxonase polymorphism:  a new enzyme assay, population, family, biochemical and linkage studies.  Am. J. Hum. Genet. 35:393-408.

Ortigoza-Ferado, J., Richter, R., Hornung, S. K., Motulsky, A. G. and Furlong, C. E.  1984.  Paraoxon hydrolysis in human serum mediated by a genetically variable arylesterase and albumin.  Am. J. Hum. Genet. 36:295-305.

Furlong, C. E., Richter, R. J., Seidel, S. L. and Motulsky, A. G.  1988.  Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. Am. J. Hum. Genet. 43: 230-238.

Furlong, C.E., R.J. Richter, S.L. Seidel, L.G. Costa and A.G. Motulsky.  Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/arylesterase.  1989.  Anal. Biochem. 180:242-247.

Costa, L.G., B.E. McDonald, S.D. Murphy, G.S. Omenn, R.J. Richter, A.G. Motulsky and C.E. Furlong.  1990. Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats.  Toxicol. Appl.  Pharmacol. 103:66-76.

Furlong, C.E., Richter, R.J., Chapline, C. and Crabb, J.W.  1991.  Purification of rabbit and human serum paraoxonase.  Biochemistry 30:10133-10140.

Hassett, C., Richter, R.J. Humbert, R., Chapline, C., Crabb, J.W., Omiecinski, C.J. and Furlong, C.E.  1991.  Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence.  Biochemistry 30:10141-10149.

Humbert, R., D.A. Adler, C.M. Disteche, C. Hassett, C.J. Omiecinski and C.E. Furlong.  1993.  The molecular basis of the human serum paraoxonase activity polymorphism.  Nature Genetics 3:73-76.

Li, W.-F., L.G. Costa, and C.E. Furlong,  1993.  Serum paraoxonase status: a major factor in determining resistance to organophosphates.  J. Toxicol. Environ. Health.  40:337-346.

Li, W.-F., C. E. Furlong and L.G. Costa.. 1995.  Paraoxonase protects against chlorpyrifos toxicity in mice.  Toxicol. Lett 76:219-226.

Clendenning, J.B., R. Humbert, E.D. Green, C.Wood, D. Traver and C.E. Furlong.  1996.  Structural organization of the human PON1 gene. Genomics 35:586-589.

Nevin, D.N., A. Zambon, C.E. Furlong, R.J. Richter, R. Humbert and J.D. Brunzell.  Paraoxonase genotypes, lipoprotein lipase activity and high density lipoproteins.  1996.  Arterioscler. Thromb. Vasc. Biol.  16:1243-1249.

Yuknavage, K.L., R.A. Fenske, D.A. Kalman, M. C. Keifer, C.E. Furlong.  1997.  Simulated dermal contamination with capillary samples and field cholinesterase biomonitoring. J. Toxicol. and Env. Health 51:35-55.

Li, W.-F., L.G. Costa and C.E. Furlong.  1997.  Paraoxonase (Pon1) gene in mice: sequencing, chromosomal location, and developmental expression. Pharmacogenetics 7:137-144.

Shih DM, Gu L, Xia Y-R, Navab M, Li W-F, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ.  1998. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394:284-287.

Richter, RJ and Furlong, CE. 1999. Determination of paraoxonase (PON1) status requires more than genotyping.  Pharmacogenetics 9:745-753.

Brophy, V.H., G.P. Jarvik, R.J. Richter, L.S. Rozek, G.D. Schellenberg and C.E. Furlong. 2000.  Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotype. Pharmacogenetics 10:453-460.

Jarvik, G.P., L.S. Rozek, V.H. Brophy, T.S. Hatsukami, R.J. Richter, G.D. Schellenberg, C.E. Furlong.  2000.  Paraoxonase phenotype is a better predictor of vascular disease than PON1192 or PON155 genotpye.  Atheroscler. Thromb. Vasc. Biol. 20:2442-2447.

Li W.-F., L.G. Costa, R.J. Richter, T. Hagen, D.M. Shih, A. Tward, A.J. Lusis and C.E. Furlong.  2000.  Catalytic efficiency determines the in vivo efficacy of PON1 for detoxifying organophosphates.  Pharmacogenetics 10:767-780.

Brophy, V.H., M.D. Hastings, J.B. Clendennning, R.J. Richter, G.P. Jarvik and C.E. Furlong.  2001.  Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 11:77-84.

Brophy, V.H., R.L. Jampsa, J.B. Clendenning, L.A. McKinstry, G.P. Jarvik and C.E. Furlong.  2001. Effects of 5' regulatory region polymorphisms on paraoxonase (PON1) expression.  Am J Hum Genet 68:1428-1436.

Document info
Document views161
Page views162
Page last viewedThu Jan 19 11:39:05 UTC 2017